Reviews
GLP-1 provider reviews
Every provider we've put through the WeighScore rubric, with its grade and one-line read. Tap any provider for the full factor breakdown. Shopping a molecule? Start with the best semaglutide providers.
- ACoreAge Rx#1 · 94/100Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
- A−Eden#2 · 90/100High-disclosure, high-oversight compounded program with the cleanest verification signals.
- B+ShedRx#3 · 88/100The widest formulation spread on the board — oral/sublingual routes plus standard injection.
- B+Ondra Health#4 · 87/100Lowest semaglutide sticker on the board ($93) paired with some brand-name access and LegitScript verification.
- BInvigor Medical#5 · 86/100An established pharmacy operator with steady mid-market pricing and a broad catalog.
- BTrimi#6 · 86/100Bottom-quartile pricing on both molecules under one flat membership, shipped free nationwide — a strong-value pick sitting just behind the top tier.
- BVitara RX#7 · 86/100Sub-$100 semaglutide and $149 tirzepatide — both molecules, verified and nationwide.
- BGala Health#8 · 86/100A low-entry compounded tirzepatide program (from $149 microdose) that reaches all 50 states and keeps a brand-name Ozempic path open — a rare combination this far up the value tier.
- BHealthRX#9 · 86/100A LegitScript-certified (#50087439) physician-supervised program that runs a rare oral GLP tablet alongside the usual injectables — compounded semaglutide from ~$189/mo, tirzepatide/GLP+GIP up to ~$349, with a brand Ozempic pass-through if you need it.
- BCare Clinics#10 · 85/100The cheapest both-molecule pairing on the board ($100/$133) from a LegitScript-verified operator.
- BNewSelf#11 · 85/100Round-$100 semaglutide, $144 tirzepatide, verified and available in all 50 states.
- BGimme Care#12 · 85/100Mid-value both-molecule pricing ($130/$163), verified, and nationwide.
- BEnhance MD#13 · 85/100A transparently tiered compounded program — semaglutide $212/mo (first month $112), tirzepatide $280, a $169 microdose, and a $322 combo — backed by six-month lab testing and provider care, with NAD+ on the side.
- BEffecty#14 · 84/100Mid-market pricing offset by brand-name access and LegitScript verification, all 50 states.
- BAgelessRx#15 · 84/100Among the lowest compounded-semaglutide pricing, with some brand-name access.
- BFresh Day Meds#16 · 84/100Tight both-molecule spread ($133/$166), verified and nationwide.
- BKongo#17 · 84/100Cheap semaglutide ($119) but a steeper tirzepatide step-up ($229); verified, nationwide.
- BPrecision Telemed#18 · 84/100Round mid-market pricing ($149/$199), verified and available nationwide.
- BMint Med#19 · 84/100Low both-molecule pricing ($117/$159) and verified — but only 36 states.
- BbmiMD#20 · 84/100Among the cheapest both-molecule pairings ($99/$139), nationwide — but not LegitScript-listed.
- BAmberHealth#21 · 83/100Round-$100 semaglutide nationwide, though tirzepatide runs $175 and it isn't verified.
- BPepHaūs#22 · 83/100Verified and nationwide, but priced in the upper-mid band ($152/$246).
- B−Found#23 · 82/100Aggressive identical pricing on both molecules, wrapped in a coaching-first program.
- B−Elara Health and Wellness#24 · 82/100Low-ish both-molecule pricing ($117/$196), nationwide — but unverified.
- B−Piper#25 · 82/100Mid-value both-molecule pricing ($135/$199), nationwide, though not verified.
- B−Direct Meds#26 · 82/100One of the few programs offering an oral/sublingual route alongside injectable — semaglutide from ~$179 sublingual (~$297 injectable), tirzepatide ~$224/$399, with an intro promo near $147, all-inclusive and no membership.
- B−Hims & Hers#27 · 80/100Mass-market app-first program with nationwide reach and consumer-grade polish.
- B−NP2GO#28 · 80/100Both molecules across 40 states, but upper-mid pricing and no verification listing.
- C+Ro#29 · 78/100A heavyweight platform with brand-name access — but opaque compounded pricing drags its score.
- CHenry Meds#30 · 76/100A flat-fee compounded pioneer — simple, but priced at the higher end of the board now.